<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953589</url>
  </required_header>
  <id_info>
    <org_study_id>BLX883-204</org_study_id>
    <nct_id>NCT00953589</nct_id>
  </id_info>
  <brief_title>480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)</brief_title>
  <acronym>480S</acronym>
  <official_title>480 STUDY: Phase 2b Open-label, Randomized Study in Treatment Naïve Subjects With HCV G1 to Compare the Efficacy, Safety, and Tolerability of the 480 µg Dose of Locteron™ Plus Ribavirin Given Bi-Weekly to PEG-Intron™ Plus Ribavirin Given Weekly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biolex Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biolex Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this 12-week study was to assess in subjects with chronic hepatitis C&#xD;
      (treatment-naïve, genotype 1) receiving weight-based doses of ribavirin the early virologic&#xD;
      response to the 480 ug dose level of Locteron™, dosed every 2 weeks, in comparison with 1.5&#xD;
      ug/kg PEG-Intron™ dosed weekly.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the 480 STUDY was to compare efficacy and safety of 480ug Locteron dosed every&#xD;
      other week to 1.5 ug/kg PegIntron dosed weekly in treatment-naïve genotype-1 chronic HCV&#xD;
      subjects treated with weight-based ribavirin. This 12-week study was comprised of two panels&#xD;
      (Panel A and Panel B). The designs of both panels were identical. HCV RNA was measured weekly&#xD;
      for three weeks and then every other week. Adverse events including flu-like events and&#xD;
      depression were collected during weekly clinic visits for 12 weeks. Flu-like events were also&#xD;
      collected daily for 12 weeks by subject self-report using the internet (ePRO). Beck&#xD;
      Depression Inventory (BDI) and Short Form-36 scores were measured at baseline and monthly&#xD;
      through Week 12.&#xD;
&#xD;
      In Panel A of 480 STUDY, 42 treatment-naïve subjects with chronic genotype-1 HCV in Bulgaria&#xD;
      and Romania were randomized and dosed with either Locteron q2weeks or weekly PegIntron, both&#xD;
      in combination with weight-based ribavirin (13). In Panel A, 19 subjects received 480ug&#xD;
      Locteron and 23 subjects received PegIntron.&#xD;
&#xD;
      In Panel B of 480 STUDY, 32 treatment-naïve subjects with genotype-1 HCV in Israel were&#xD;
      randomized and dosed with either Locteron q2weeks or weekly PegIntron, both in combination&#xD;
      with weight-based ribavirin (13). In Panel B, 16 subjects received 480ug Locteron and 16&#xD;
      subjects received PegIntron.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy endpoint: EVR: the proportion of subjects in each arm that have at least a 2 log drop in HCV RNA from Baseline</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects in each arm demonstrating HCV RNA undetectable (&lt; 10 IU/mL) after 12 weeks of randomized treatment</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Locteron ® PANEL A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PANEL A: Locteron™ 480 µg dosed every 2 weeks in two subcutaneous injections (160 µg and 320 µg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Locteron ® PANEL B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PANEL B: Locteron™ 480 µg dosed every two weeks in single subcutaneous injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-Intron® PANEL A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-Intron® PANEL B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>Ribavirin - oral administration Subjects with body weight &lt; 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight &gt; 105 kg: 1400 mg/day</description>
    <arm_group_label>Locteron ® PANEL A</arm_group_label>
    <arm_group_label>Locteron ® PANEL B</arm_group_label>
    <arm_group_label>PEG-Intron® PANEL A</arm_group_label>
    <arm_group_label>PEG-Intron® PANEL B</arm_group_label>
    <other_name>Ribasphere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects 18 through 69 years of age, inclusive&#xD;
&#xD;
          -  Chronic hepatitis C genotype 1&#xD;
&#xD;
          -  HCV ribonucleic acid (RNA) level &gt; 10,000 IU/mL (by RT-PCR) at screening&#xD;
&#xD;
          -  Creatine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Neutrophil count &gt; 1500 cells/mm3&#xD;
&#xD;
          -  Platelet count &gt; 90,000/mm3&#xD;
&#xD;
          -  Hemoglobin &gt; 12 g/dL for females and &gt; 13 g/dL for males&#xD;
&#xD;
          -  Female subjects of child-bearing potential agreeing to use dual methods for&#xD;
             contraception&#xD;
&#xD;
          -  Male subjects with female sexual partners agreeing to use effective birth control&#xD;
             methods&#xD;
&#xD;
          -  Negative serum pregnancy test for women of child-bearing potential&#xD;
&#xD;
          -  Compensated liver disease defined as INR &lt; 1.5, conjugated bilirubin &lt; 1.5 x ULN,&#xD;
             serum albumin &gt; 3.0 g/dL&#xD;
&#xD;
          -  Histologic evidence of Chronic Hepatitis C (CHC) (inflammation, fibrosis and/or&#xD;
             cirrhosis on a standardized histologic grading system) as shown by biopsy within 2&#xD;
             years of screening or agrees to have a liver biopsy performed prior to randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior antiviral treatment for hepatitis C&#xD;
&#xD;
          -  Co-infection with HIV or hepatitis B virus&#xD;
&#xD;
          -  Subjects with a body mass index (BMI) above 32 kg/m2&#xD;
&#xD;
          -  Current or prior history of clinical hepatic decompensation&#xD;
&#xD;
          -  Evidence of HCC&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus as evidenced by HbA1C ≥ 8.5% at screening&#xD;
&#xD;
          -  Known hypersensitivity to interferon alfa or ribavirin&#xD;
&#xD;
          -  Chronic liver disease other than HCV&#xD;
&#xD;
          -  Clinically significant hemoglobinopathy&#xD;
&#xD;
          -  History of moderate, severe or uncontrolled psychiatric disease including depression&#xD;
             and prior suicide attempts&#xD;
&#xD;
          -  History of immune-mediated disease&#xD;
&#xD;
          -  Significant renal or neurological disease&#xD;
&#xD;
          -  Severe degree (&gt; GOLD stage III) of chronic pulmonary disease (COPD) or active, severe&#xD;
             asthma&#xD;
&#xD;
          -  Subjects with severe cardiac disease&#xD;
&#xD;
          -  History of significant central nervous system (including CNS trauma) or seizure&#xD;
             disorders&#xD;
&#xD;
          -  Cancer within the last 5 years, or previous cancer with a high risk of recurrence&#xD;
&#xD;
          -  History of solid organ or bone marrow transplantation&#xD;
&#xD;
          -  Clinical or laboratory evidence of uncontrolled thyroid disease, e.g., by thyroid&#xD;
             stimulating hormone (TSH) level &gt; 1.2 x upper limit of normal&#xD;
&#xD;
          -  Clinically significant retinopathy; this needs to have been excluded by an eye exam&#xD;
             performed by an ophthalmologist within the last 6 months prior to screening for&#xD;
             subjects with hypertension or diabetes mellitus&#xD;
&#xD;
          -  Drug abuse or alcohol consumption within the last 6 months which, in the opinion of&#xD;
             the investigator, may affect study participation or outcome. Subjects in a supervised&#xD;
             methadone treatment program on a stable regimen for &gt; 6 months may be considered&#xD;
&#xD;
          -  Taken any experimental agent within 12 weeks prior to screening&#xD;
&#xD;
          -  More than 30 days of systemic immunosuppressive medication to include steroids in&#xD;
             doses equivalent to or greater than 10 mg prednisone per day within 30 days prior to&#xD;
             screening (inhaled corticosteroids are allowed)&#xD;
&#xD;
          -  Nursing mother or male partner of pregnant female.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walker A. Long, MD</last_name>
    <role>Study Director</role>
    <affiliation>Biolex Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tokuda Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Alexandrovska&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;St Ivan Rilski&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Queen Giovanna - ISUL&quot; EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Institute Ministry of Interior</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;St Maria&quot;</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34341</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Family Hospital Nazareth</name>
      <address>
        <city>Nazareth</city>
        <zip>16100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah-Tiqwa</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rebekah Ziv Medical Center Safed</name>
      <address>
        <city>Zefat</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Infectious Diseases</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundeni Clinical Institute</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Victor Babes&quot; Clinical Hospital Craiova</name>
      <address>
        <city>Craiova</city>
        <zip>200515</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology and Hepatology Institute</name>
      <address>
        <city>Iasi</city>
        <zip>700111</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Israel</country>
    <country>Romania</country>
  </location_countries>
  <reference>
    <citation>Krastev Z, Kotzev I, Tchernev K, Rigney A, Nikolovska D, Vladimirov B, Caruntu FA, Diaconescu IG, Voiculescu XX, Long, WA. Randomized, open-label, 12-week comparison of controlled-release interferon alpha2b + ribavirin vs. pegylated interferon alpha 2b +ribavirin in treatment-naïve genotype1 hepatitis C: 4 week results from 480STUDY (Panel A). J Hepatology 52:S27 (abstract 58), 2010. (Presented to 45th Annual Meeting of the European Association for the Study of the Liver, April 16, 2010, Vienna, Austria.)</citation>
  </reference>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>August 5, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <last_update_submitted>February 1, 2012</last_update_submitted>
  <last_update_submitted_qc>February 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

